Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

theranoimmuno

Financiado

Theranostic Immune Cell

Recent studies on the developments of immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC), bispecific T-cell receptors (TCR) engagers, and chimeric antigen receptor (CAR) cell-based therapies, have highlighted th... ver más

28/02/2026

GCS INSTITUT DE CA...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

GCS INSTITUT DE CANCEROLOGIE STRASBOURG EUROP... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-02-19

ERC-2020-STG: ERC STARTING GRANTS

I+D

Cerrada hace 5 años

0% 100% 100%

3 Participantes

GCS INSTITUT DE CANCEROLOGIE...

890.36K€ | Lider

ORMAZABAL Y COMPAÑIA

437.82K€ | Participante

CNRS

590.63K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-125734OB-I00 CD229 EN EL MIELOMA MULTIPLE: BIOLOGIA Y DIANA TERAPEUTICA 242K€ Cerrado

SweetAim Selective glycoimmuno targeting for cancer therapy 1M€ Cerrado

RTC-2016-5118-1 Inmunoterapia del cáncer mediante anticuerpos coestimuladore... 313K€ Cerrado

Crosstag Unravelling cross presentation pathways using a chemical bio... 2M€ Cerrado

PDT-NEO-immunother Generation of tumor neoantigens with photodynamic therapy: a... 176K€ Cerrado

PID2020-118529RB-I00 EXPLOTANDO LOS DETERMINANTES MOLECULARES DE LA RESPUESTA T A... 218K€ Cerrado

Duración del proyecto: 60 meses Fecha Inicio: 2021-02-19
Fecha Fin: 2026-02-28

Líder del proyecto

GCS INSTITUT DE CANCEROLOGIE STRASBOURG EUROP... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Descripción del proyecto Recent studies on the developments of immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC), bispecific T-cell receptors (TCR) engagers, and chimeric antigen receptor (CAR) cell-based therapies, have highlighted their potential to treat Multiple Myeloma (MM). These treatments, however, are expensive. The manufacturing processes that are employed for their generation are lengthy, and their commercial scale production is reliant on a multitude of equipment and operators that cannot easily be incorporated in the footprint of most local hospitals. Moreover, patient responses to these treatments remain heterogenous. We propose an innovative multidisciplinary approach that aims to develop a novel theranostic immune-cell based compound. This approach is based on the functionalization of the immune cells with theranostic ultrasmall macromolecules (USM); USM having a diameter size below 10 nm to allow renal clearance and minimize toxicity. The clinically-relevant imaging properties of the USM will allow to unveil various challenges remaining in the field of immunotherapy, such as to better elucidate the priming sites of immune cells, to track their migration in the body, as well as to localize their niche upon the establishment of minimal residual disease. By labelling the immune cells ex vivo, the diagnostic imaging properties enabled by the presence of the USM on the immune cell surface will allow to generate better ex vivo immune cells therapeutics (such as simili-CAR NK cells) with a rationalized target selection, will improve the cell dosing, and will help to better stratify the patient population in order to offer an improved personalized treatment plan.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores